Meeting NewsVideo

VIDEO: Joint blockade of PD-1, CTLA-4 is ‘viable option’ in melanoma

NEW YORK — Steven J. O’Day, MD, executive director of John Wayne Cancer Institute, spoke at HemOnc Today New York about efforts to find the right partner for anti-PD-1 therapy for patients with melanoma.

O’Day focused largely on CTLA-4 as a major target.

“We now have clear data in a phase 3 setting ... showing the combination of CTLA-4 blockade and PD-1 blockade improves survival, with 53% of patients alive at 4 years with the combination,” O’Day told HemOnc Today. “This does have added toxicity, but toxicity management has evolved, and this is now a viable FDA-approved option as a partner for PD-1 in advanced melanoma.”

O’Day also discussed other promising new drugs, including tumor microenvironment agents and those designed to activate the priming response.

“There are a variety of combinations of T-cell targets, as well as off-T-cell targets, that are being combined with PD-1 in advanced malignancies across solid tumors,” O’Day said.

NEW YORK — Steven J. O’Day, MD, executive director of John Wayne Cancer Institute, spoke at HemOnc Today New York about efforts to find the right partner for anti-PD-1 therapy for patients with melanoma.

O’Day focused largely on CTLA-4 as a major target.

“We now have clear data in a phase 3 setting ... showing the combination of CTLA-4 blockade and PD-1 blockade improves survival, with 53% of patients alive at 4 years with the combination,” O’Day told HemOnc Today. “This does have added toxicity, but toxicity management has evolved, and this is now a viable FDA-approved option as a partner for PD-1 in advanced melanoma.”

O’Day also discussed other promising new drugs, including tumor microenvironment agents and those designed to activate the priming response.

“There are a variety of combinations of T-cell targets, as well as off-T-cell targets, that are being combined with PD-1 in advanced malignancies across solid tumors,” O’Day said.

    See more from HemOnc Today New York